Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of the best hot stocks to invest in. On October 8, Guggenheim initiated coverage of Olema Oncology with a Buy rating and $20 price target. The firm views Olema as the top biotech for selective estrogen receptor degrader/SERD breast cancer drugs. Guggenheim cited its palazestrant as the most promising drug in a $10 billion market.

The company discovers and develops targeted therapies for breast cancer and beyond. A key highlight was the selection of a 90 mg once-daily dose of its lead product candidate, palazestrant (OP-1250), for Part 2 of the ongoing pivotal OPERA-01 Phase 3 monotherapy trial and for the planned pivotal OPERA-02 Phase 3 trial.

Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

In Q2 2025, Olema reported a Net Loss of $43.8 million for the quarter, compared to a net loss of $30.4 million for Q2 2024. The increase in net loss was due to increased R&D spending related to the late-stage trials for palazestrant and the advancement of OP-3136.

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes therapies for women’s cancers.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.